60¢sixtycents

Gilead Sciences, Inc.GILD

$123.76-1.69 (-1.35%)
NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap
$155B
Large-cap
+41%
2016 — today
10-Year Price
+59%
2016 — today
52-Week Range
$105.93$155.80
Current $123.76· 36%

Gilead Sciences discovers, develops, and commercializes innovative therapies for critical health needs globally. Its portfolio includes HIV treatments (Biktarvy, Genvoya, Descovy, Truvada), the COVID-19 antiviral Veklury, and liver disease medications (Epclusa, Harvoni, Vemlidy). It also addresses hematology, oncology, and cell therapy (Yescarta, Tecartus, Trodelvy), alongside treatments for pulmonary arterial hypertension and fungal infections. Gilead collaborates with partners like Merck and BMS to advance its pipeline.

Valuation in context

P/E ratio
16.9
Below average
Below the 10-year average
P/B ratio
6.6
Historically pricey
Historically pricey — last 10 years
EV / EBITDA
12.1
Around average
Around the 10-year average
Dividend Yield
2.6%
Historically low
Historically low relative to the last 10 years
PEG ratio
0.2
Historically cheap
Historically cheap relative to the last 10 years
FCF Yield
6.6%
Near historic low
Near historic low — last 10 years
Free · No credit card needed

Get alerted when GILD is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.